<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="39015">Apolipoprotein</z:chebi> E gene (APOE) polymorphism is an important determinant for the development of various cardiovascular and <z:e sem="disease" ids="C0524851" disease_type="Disease or Syndrome" abbrv="">neurodegenerative disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>There have been conflicting reports of association of APOE polymorphism with <z:hpo ids='HP_0000726'>dementia</z:hpo> in <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To determine the relationship between APOE polymorphisms and plasma cholesterol concentration, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> with <z:hpo ids='HP_0000726'>dementia</z:hpo> (PDD) </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: Four-year (1999-2002) case-control study </plain></SENT>
<SENT sid="4" pm="."><plain>SETTING: Academic medical center with inpatient and outpatient <z:hpo ids='HP_0100022'>movement disorders</z:hpo> services </plain></SENT>
<SENT sid="5" pm="."><plain>Patients Consecutive white patients of the same ethnic background with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>INTERVENTIONS: Strict clinical, neuropsychological, and neuroimaging criteria were used to exclude <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo>, <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo>, and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Findings were compared in 2 clinical groups, including 98 patients (47 men and 51 women; mean age, 71 years) with PDD and 100 patients (52 men and 48 women; mean age, 62 years) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> without <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>MAIN OUTCOME MEASURES: Analysis of APOE genotypes and allelic frequency (polymerase chain reaction) and plasma cholesterol concentration (enzymatic assay) were evaluated by a clinician blinded to the clinical diagnosis, and findings were compared between the groups with PDD or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> without <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Multiple stepwise regression analysis and the Spearman rank correlation coefficient were used to evaluate relationships between <z:hpo ids='HP_0000726'>dementia</z:hpo> and both APOE polymorphism and cholesterol concentration </plain></SENT>
<SENT sid="10" pm="."><plain>Statistical significance was set at P&lt;.05 </plain></SENT>
<SENT sid="11" pm="."><plain>RESULTS: Epsilon4 allele frequencies were similar in PDD and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> without <z:hpo ids='HP_0000726'>dementia</z:hpo> (16.8% vs 19%, respectively) </plain></SENT>
<SENT sid="12" pm="."><plain>Cholesterol concentration, APOE genotypes, and allelic frequencies did not relate to PDD </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: In contrast to <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo>, when PDD is carefully defined, it is clearly not associated with APOE polymorphisms or with a distinctive plasma cholesterol profile </plain></SENT>
<SENT sid="14" pm="."><plain>Ongoing longitudinal follow-up with emphasis on autopsy recruitment will enable further analyses of biochemical alterations underlying PDD </plain></SENT>
</text></document>